<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Merck (MRK) And Daiichi Sankyo's R-DXd Receives FDA Breakthrough Therapy Designation</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Merck (MRK) And Daiichi Sankyo's R-DXd Receives FDA Breakthrough Therapy Designation</h1>
  <ul>
<li>Current share prices reflect a discount of approximately 23.6% compared to the consensus analyst price target of US$102.33.</li>
<li>Over the past five years, Merck's total shareholder return, incorporating both share price appreciation and dividends, was 21.17%.</li>
<li>Notably, its yearly performance has also been weaker compared to peers in the US Pharmaceuticals industry, which saw a 12.5% decline.</li>
<li>This figure illustrates a steady growth trajectory, yet the company has underperformed the US market's 18.5% return over the past year.</li>
<li>Merck experienced a 6% rise in its share price over the last quarter, coinciding with significant developments such as the FDA granting Breakthrough Therapy Designation for raludotatug deruxtecan—a potential first-in-cla</li>
<li>Find out which 28 stocks are leading the charge.</li>
<li>We've discovered 1 weakness for Merck that you should be aware of before investing here.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/merck-mrk-daiichi-sankyos-r-172714735.html">Source</a> · 2025-09-15T17:27:14+00:00</p>
</body>
</html>